27 
“ Gnomon ” comments on the article in the Druggists Circular 
and calls attention to the growing custom of registering trade-marks 
before taking out letters patent, so as to secure the continuance of 
trade-mark rights after the expiration of the letters patent. — Pharm. 
J. Lond., 1905, v. 21, p. 442. 
The editor discusses the abuses that have arisen in Germany in 
connection with the protection that is granted for the name of a 
medicinal article. — Apoth. Ztg. Berlin, 1905, v. 20, p. 902. 
Rathenau, an attache of the imperial (German) patent office, has 
published a lengthy dissertation on the rights and the limitations 
of trade names. The article is abstracted at some length.— Ibid., 
p. 665. 
An unsigned article comments at some length on an article on 
the United States and French trade-mark laws as contrasted with 
those of German} 7 and the South American Republics. — Xat. Drug., 
St. Louis, 1905, v. 35, p. 264. 
4. NEW REMEDIES. 
Bearing closely on the admission of synthetic products into the 
pharmacopoeia is the question of regulation of new remedies that 
is being discussed in various parts of the world. 
The inauguration of the council on pharmacy and chemistry of 
the American Medical Association attracted considerable attention, 
and the work done by this council and by other bodies in different 
parts of the world will no doubt do much to differentiate between 
the true and the false in new remedies. 
The rules of the council on pharmacy and chemistry are designed 
as requirements with which new remedies are expected to comply. — 
J. Am. M. Ass., Chicago, 1905, v. 44, p. 718-721. 
A circular letter signed by the presiding officers of the German, 
Austrian, and Swiss pharmaceutical societies calls attention to the 
need for definite and authentic information regarding new remedies 
and outlines suggestions as to the form in which this information is 
to be given. — J. d. Pharm. v. Elsass-Lothr. Mulhausen, 1905, v. 32, 
pp. 136-140. 
Golaz-Vevey is credited with criticising the nomenclature of new 
remedies, which depends altogether too greatly on an ending in al, 
en, ic, in, or ol, of a name that is frequently fantastic, or at best 
based but loosely on the chemical composition or the therapeutic 
possibilities of the new remedy. He outlines the following as being 
indicative of the information that the apothecary should have: 
(а) The commercial as well as the exact chemical name. 
(б) Satisfactory tests for identity and purity. 
(c) Melting and boiling points. 
